Canaccord Genuity Keeps a Sell Rating on Cronos Group Inc

In a latest note to investors, a research analyst has provided a rating update for the Financial sector company, Cronos Group Inc (TSXV: CRON). Canaccord Genuity’s analyst Matt Bottomley reiterates their Sell rating on the shares, with a C$6.50 price target.

Bottomley has an average return of 38.9% when recommending Cronos Group Inc.

According to, Bottomley is ranked #176 out of 4800 analysts.

Cronos Group Inc has an analyst consensus of Hold, with a price target consensus of C$6.75.

Based on Cronos Group Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of C$2.06 million. In comparison, last year the company had a GAAP net loss of C$844.4K.

Cronos Group, Inc. engages in the production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. Its portfolio includes Peace Naturals, Original BC (OGBC) and Whistler Medical Marijuana Company (WMMC). The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

The company’s shares closed on Tuesday at C$8.

From Our Partners